project id: TCGA-PRAD; case submitter id: TCGA-EJ-A8FN; analyte type: DNA; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.88; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.31; rna integrity number: 8.0; age at index: 58; days to birth: -21506; ethnicity: not reported; gender: male; race: white; vital status: Alive; year of birth: 1955; age at diagnosis: 21506; ajcc clinical m: M0; ajcc clinical t: T2c; ajcc pathologic n: N0; ajcc pathologic t: T2c; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 329.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 3; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 203; initial weight: 330.0; sample id: f2f0aac0-2c24-4207-b76f-24933d10c712; sample submitter id: TCGA-EJ-A8FN-01A; portion id: d61dbdde-2809-44db-9d1d-96cd9956271a; portion submitter id: TCGA-EJ-A8FN-01A-11; slide id: c6ec1b27-a3f7-4dd5-9851-8333c5a7463a; slide submitter id: TCGA-EJ-A8FN-01A-01-TSA; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 50.0; percent stromal cells: 0.0; percent tumor cells: 50.0; percent tumor nuclei: 60.0; section location: TOP;